These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37678974)

  • 1. Universal and hypoimmunogenic pluripotent stem cells for clinical usage.
    Sung TC; Maitiruze K; Pan J; Gong J; Bai Y; Pan X; Higuchi A
    Prog Mol Biol Transl Sci; 2023; 199():271-296. PubMed ID: 37678974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of universal and hypoimmunogenic human pluripotent stem cells.
    Ye Q; Sung TC; Yang JM; Ling QD; He Y; Higuchi A
    Cell Prolif; 2020 Dec; 53(12):e12946. PubMed ID: 33174655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient characteristics of universal cells on human-induced pluripotent stem cells and their differentiated cells derived from foetal stem cells with mixed donor sources.
    Sung TC; Jiang YP; Hsu JY; Ling QD; Chen H; Kumar SS; Chang Y; Hsu ST; Ye Q; Higuchi A
    Cell Prolif; 2021 Mar; 54(3):e12995. PubMed ID: 33522648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a baculoviral CRISPR/Cas9 vector system for beta-2-microglobulin knockout in human pluripotent stem cells.
    Xiang Z; Ye Q; Zhao Z; Wang N; Li J; Zou M; Lau CH; Zhu H; Wang S; Ding Y
    Mol Genet Genomics; 2024 Aug; 299(1):74. PubMed ID: 39085666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity.
    Tsuneyoshi N; Hosoya T; Takeno Y; Saitoh K; Murai H; Amimoto N; Tatsumi R; Watanabe S; Hasegawa Y; Kikkawa E; Goto K; Nishigaki F; Tamura K; Kimura H
    Stem Cell Res Ther; 2024 Jul; 15(1):193. PubMed ID: 38956724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy.
    Mattapally S; Pawlik KM; Fast VG; Zumaquero E; Lund FE; Randall TD; Townes TM; Zhang J
    J Am Heart Assoc; 2018 Dec; 7(23):e010239. PubMed ID: 30488760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
    Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
    Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine.
    Trionfini P; Romano E; Varinelli M; Longaretti L; Rizzo P; Giampietro R; Caroli A; Aiello S; Todeschini M; Casiraghi F; Remuzzi G; Benigni A; Tomasoni S
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of hypoimmunogenic human pluripotent stem cells.
    Han X; Wang M; Duan S; Franco PJ; Kenty JH; Hedrick P; Xia Y; Allen A; Ferreira LMR; Strominger JL; Melton DA; Meissner TB; Cowan CA
    Proc Natl Acad Sci U S A; 2019 May; 116(21):10441-10446. PubMed ID: 31040209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of hypoimmunogenic human pluripotent stem cells via expression of membrane-bound and secreted β2m-HLA-G fusion proteins.
    Shi L; Li W; Liu Y; Chen Z; Hui Y; Hao P; Xu X; Zhang S; Feng H; Zhang B; Zhou S; Li N; Xiao L; Liu L; Ma L; Zhang X
    Stem Cells; 2020 Nov; 38(11):1423-1437. PubMed ID: 32930470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoimmunogenic human pluripotent stem cells are valid cell sources for cell therapeutics with normal self-renewal and multilineage differentiation capacity.
    Chen Y; Zhou Y; Zhou Z; Fang Y; Ma L; Zhang X; Xiong J; Liu L
    Stem Cell Res Ther; 2023 Jan; 14(1):11. PubMed ID: 36691086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 Ribonucleoprotein Complex-Mediated Efficient B2M Knockout in Human Induced Pluripotent Stem Cells (iPSCs).
    Thongsin N; Wattanapanitch M
    Methods Mol Biol; 2022; 2454():607-624. PubMed ID: 33945142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy.
    de Rham C; Villard J
    J Immunol Res; 2014; 2014():518135. PubMed ID: 25126584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering strategies for generating hypoimmunogenic cells with high clinical and commercial value.
    Malik NN; Jenkins AM; Mellon J; Bailey G
    Regen Med; 2019 Nov; 14(11):983-989. PubMed ID: 31663432
    [No Abstract]   [Full Text] [Related]  

  • 15. Maintenance of Hypoimmunogenic Features
    An JH; Koh H; Ahn Y; Kim J; Han AR; Lee JY; Kim SU; Lee JH
    Front Bioeng Biotechnol; 2022; 10():936584. PubMed ID: 36032723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac Regeneration Using Pluripotent Stem Cells and Controlling Immune Responses.
    Ichimura H; Chino S; Shiba Y
    Heart Lung Circ; 2023 Jul; 32(7):836-843. PubMed ID: 37029069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells.
    Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L
    Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells.
    Gornalusse GG; Hirata RK; Funk SE; Riolobos L; Lopes VS; Manske G; Prunkard D; Colunga AG; Hanafi LA; Clegg DO; Turtle C; Russell DW
    Nat Biotechnol; 2017 Aug; 35(8):765-772. PubMed ID: 28504668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generating hypoimmunogenic human embryonic stem cells by the disruption of beta 2-microglobulin.
    Lu P; Chen J; He L; Ren J; Chen H; Rao L; Zhuang Q; Li H; Li L; Bao L; He J; Zhang W; Zhu F; Cui C; Xiao L
    Stem Cell Rev Rep; 2013 Dec; 9(6):806-13. PubMed ID: 23934228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.